Published document record
Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle
PDF source copies
These PDFs are hosted here for continued access. Each is labelled as an unmodified official PDF or a converted reading copy. They are saved copies, not a live statement of the latest law or institutional endorsement. Official source links remain below.
Official PDF — unmodified source copy
If the PDF does not display in your browser, Open PDF in a new tab or download it below. Both use the copy hosted on this site.
Download PDF — 18 pages (0.37 MB)EMA/CHMP/CVMP/83833/2023. Final reflection paper.
Source: European Medicines Agency. Retrieved 2026-09-10.
Copy provenance and reuse
Unmodified source PDF. Source attribution and original notices are retained; see the source reuse terms. Source reuse terms. The database metadata licence does not replace these terms.
SHA-256:
975c220bdfd7243917dff6462c0e44f2ca650f7f20c7c956806de4ac23fac11b
Official metadata
- Official title
- Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle
- Official reference
- EMA/CHMP/CVMP/83833/2023
- Document type
- Guidelines
- Document date
- 2024-09-09
- Document date kind
- Document issue
- Document-date evidence
- European Medicines Agency · PDF cover heading: 9 September 2024. — Exact issue date printed on this version.
- Publication date
- 2024-09-30
- Publication-date evidence
- European Medicines Agency · Current version: First published 30/09/2024. — Establishes official publication of this version on 2024-09-30, before the 4 September 2026 cutoff.
- Additional official dates
- Institutional adoption: 2024-09-09 (day) · European Medicines Agency · Cover adoption table: CHMP final adoption.
- Institutional adoption: 2024-09-11 (day) · European Medicines Agency · Cover adoption table: CVMP final adoption.
- Version label
- Final reflection paper
- Legal status
- Non binding
- Legal-status evidence
- European Medicines Agency · PDF cover; pp.3-4 Introduction and scope; pp.8-12 technical and governance considerations. — Non-legislative report, scientific guidance, strategic workplan or consultation text; not an act creating binding law.
- Language
- en
Research classifications
These are researcher classifications used to organise and analyse the corpus; they are not official EU metadata.
- Record level
- Principal
- Version status
- Final
- Temporal collection
- Contemporary EU AI policy
- Relevance class
- Direct AI relevance
- Policy stage
- Implementation
- Corpus tier
- Directly related
- Sectors
- Policy membership
Classification evidence
- Relevance class: Direct AI relevance · European Medicines Agency · PDF cover; pp.3-4 Introduction and scope; pp.8-12 technical and governance considerations. — AI/ML is a substantive regulatory or sectoral subject.
- Sector tags: Health · European Medicines Agency · PDF cover; pp.3-4 Introduction and scope; pp.8-12 technical and governance considerations. — Addresses medicines or health-insurance AI.
- Provenance tags: Authored by an EU agency or body · European Medicines Agency · PDF cover; pp.3-4 Introduction and scope; pp.8-12 technical and governance considerations. — Produced within the named EU agency/body; named personal author credits remain separate.
- Provenance tags: Officially published · European Medicines Agency · Official record with linked English document. — Official EU endpoint distributes this independently citable English text.
Production provenance
- Provenance tags
- Named bibliographic authors
- Committee for Medicinal Products for Human Use · European Medicines Agency · European Medicines Agency · PDF cover names both committees.
- Committee for Medicinal Products for Veterinary Use · European Medicines Agency · European Medicines Agency · PDF cover names both committees.
- Institutions and roles
-
- Committee for Medicinal Products for Human Use · Adopter · role evidence · Cover adoption table: CHMP.
- Committee for Medicinal Products for Human Use · Author · role evidence · Cover names CHMP.
- Committee for Medicinal Products for Veterinary Use · Adopter · role evidence · Cover adoption table: CVMP.
- Committee for Medicinal Products for Veterinary Use · Author · role evidence · Cover names CVMP.
- European Medicines Agency · Official host · role evidence · Official publication record and linked English PDF.
- European Medicines Agency · Publisher · role evidence · Official publication record and linked English PDF.
Official sources and identifiers
- Official source · Publisher/host: European Medicines Agency
- Official source · Publisher/host: European Medicines Agency
Previous and next versions
-
Previous version: Draft reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle
Revises · Official relationship · Verified
Research assessment
- Inclusion rationale
- AI and machine learning are the document's regulatory subject, with lifecycle-wide principles for evaluation, risk mitigation, governance, data, explainability, and trustworthy use in medicines.
- Researcher notes
- Cover issue differs from the later CVMP adoption on 11 September 2024. CHMP and CVMP are both EMA committees, not separate institutions for joint-authorship tagging.
- Review status
- verified
Relationships
No additional published relationships touch this record.
Verification
- Expanded evidence review
- Verified
- Reviewed by
- Yichen Hao
- Evidence review date
- 2026-09-05T23:48:11Z
The evidence review date is not a separate human sign-off date. Review credit and evidence-review actions
- Last verified: 2026-09-05T23:48:11Z · PDF cover heading: 9 September 2024. Official linked English manifestation reviewed.
- Last verified: 2026-09-05T23:48:11Z · PDF cover; pp.3-4 Introduction and scope; pp.8-12 technical and governance considerations. English text inspected in web extraction or Node fetch plus pypdf; no retained file snapshot claimed.